Exploratory Safety Pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations

Bibliography

• ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/LOB/media/MEDIA504.pdf
   Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
   PubMed Web of Science ®Google Scholar
• Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 2008;58:77-87
   PubMedGoogle Scholar
• Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908
   PubMed Web of Science ®Google Scholar
• Redfern WS, Wakefield ID, Prior H, Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 2002;16:161-73
   PubMed Web of Science ®Google Scholar
• Critical Path Opportunities Report. FDA 2006. Available from: www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf
   Google Scholar
• Bass A, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004;49:145-51
   PubMedGoogle Scholar
• ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/LOB/media/MEDIA2192.pdf
   Google Scholar
• Redfern WS, Wakefield ID. Safety pharmacology. In: Jacobson-Kram D, Keller KA, editors, Toxicology testing handbook. Informa Healthcare, NY, London; 2006. p. 33-78
   Google Scholar
• Guth BD. Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci 2007;97:4-20
   PubMed Web of Science ®Google Scholar
• Bass AS, Siegl PKS, Gintant GA, Current practices in safety pharmacology. In: Gad SC, editor, Preclinical development. John Wiley & Sons, Inc, NY; 2008.
   Google Scholar
• Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. Br J Pharmacol 2008;154:1382-99
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline. E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005). Available from: /www.ich.org/ LOB/media/MEDIA1476.pdf
   Google Scholar
• Cavero I. Safety pharmacology society: 9th Annual Meeting 22–25 September, 2008, Madison, USA. Expert Opinion Drug Saf 2009;8:237-47
   PubMed Web of Science ®Google Scholar
• Guidance for industry safety testing of drug metabolites, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), February 2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar
• Lindgren S, Bass AS, Briscoe R, Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008;58:99-109
   PubMedGoogle Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9
   PubMed Web of Science ®Google Scholar
• OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. 2005. Available from: www.oecd.org/dataoecd/55/35/38130292.pdf
   Google Scholar
• Valentin JP, Bialecki R, Ewart L, A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009;60:152-8
   PubMedGoogle Scholar
• Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31986L0609:EN:NOT
   Google Scholar
• Molecular operating environment. Available from: www.moleculardescriptors.eu
   Google Scholar
• OECD. Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models. Available from: www.oecd.org/dataoecd/55/35/38130292.pdf
   Google Scholar
• Aronov AM. Tuning out of hERG. Curr Opin Drug Discov Devel 2008;11:128-40
   PubMed Web of Science ®Google Scholar
• Available from: www.chemcomp.com
   Google Scholar
• Tobita M, Nishikawa T, Nagashima R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg Med Chem Lett 2005;15:2886-90
   PubMed Web of Science ®Google Scholar
• Yap CW, Cai CZ, Xue Y, Prediction of torsade-causing potential of drugs by support vector machine approach. Toxicol Sci 2004;79:170-7
   PubMed Web of Science ®Google Scholar
• Genschow E, Spielmann H, Scholz G, The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 2002;30:151-76
   PubMed Web of Science ®Google Scholar
• Muster W, Breidenbach A, Fischer H, Computational toxicology in drug development. Drug Discov Today 2008;13:303-10
   PubMed Web of Science ®Google Scholar
• Brimecombe JC, Kirsch GE, Brown AM. Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability. J Pharmacol Toxicol Methods 2009;59:29-34
   PubMedGoogle Scholar
• Cavero I, Mestre M, Guillon JM, Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf 1999;21 (Suppl 1):19-31
   PubMedGoogle Scholar
• Whitebread S, Hamon J, Bojanic D, Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-33
   PubMed Web of Science ®Google Scholar
• Redfern WS, Waldron G, Winter MJ, Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring? J Pharmacol Toxicol Methods 2008;58:110-7
   PubMedGoogle Scholar
• Guth BD, Germeye S, Kolb W, Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods 2004,49:159-69
   PubMedGoogle Scholar
• Yao X, Anderson DL, Ross SA, Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 2008;154:1446-56
   PubMed Web of Science ®Google Scholar
• Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC Neurosci 2008;9(Suppl 3):S7
   PubMedGoogle Scholar
• Available from: www.genstruct.com
   Google Scholar
• Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Lett 2005;579:1872-7
   PubMed Web of Science ®Google Scholar
• Sivachenko AY, Yuryev A. Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. Expert Opin Ther Targets 2007;11:411-21
   PubMed Web of Science ®Google Scholar
• Mayne JT, Ku WW, Kennedy SP. Informed toxicity assessment in drug discovery: systems-based toxicology. Curr Opin Drug Discov Devel 2006;9:75-83
   PubMed Web of Science ®Google Scholar
• Gao Z, Li H, Zhang H, PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
   PubMed Web of Science ®Google Scholar
• Interactive Biological Pathways Tool. Available from: www.millipore.com/pathways/pw/pathways
   Google Scholar
• Available from: www.cerep.fr/Cerep/Users/pages/ProductsServices/BioPrintServices.asp
   Google Scholar
• Bender A, Scheiber J, Glick M, Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2:861-73
   PubMed Web of Science ®Google Scholar
• Azzaoui K, Hamon J, Faller B, Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007;2:874-80
   PubMed Web of Science ®Google Scholar
• Available from: www.cerep.fr/Cerep/Users/pages/ProductsServices/BioPrintServices.asp
   Google Scholar
• Meyer T, Sartipy P, Blind F, New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 2007;3:507-17
   PubMed Web of Science ®Google Scholar
• Jensen J, Hyllner J, Björquist P. Human embryonic stem cell technologies and drug discovery. J Cell Physiol 2009;219:513-9
   PubMed Web of Science ®Google Scholar
• Kari G, Rodeck U, Dicker AP. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007;82:70-80
   PubMed Web of Science ®Google Scholar
• Barros TP, Alderton WK, Reynolds HM, Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008;154:1400-13
   PubMed Web of Science ®Google Scholar
• Eimon PM, Rubinstein AL. The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin Drug Metab Toxicol 2009;5:393-401
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Hsu CH, Wen ZH, Zebrafish: a complete animal model for in vivo drug discovery and development. Curr Drug Metab 2009;10:116-24
   PubMed Web of Science ®Google Scholar
• McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 2008;9(10):394-401
   PubMed Web of Science ®Google Scholar
• Schierok H, Markert M, Pairet M, Continuous assessment of multiple vital physiological functions in conscious freely moving rats using telemetry and a plethysmography system. J Pharmacol Toxicol Methods 2000;43:211-7
   PubMed Web of Science ®Google Scholar
• Delaunois A, Dedoncker P, Hanon E, Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. J Pharmacol Toxicol Methods 2009;60:117-29
   PubMedGoogle Scholar
• Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008;154:1528-37
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009;8:317-29
   PubMed Web of Science ®Google Scholar
• Killeen MJ. Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. Drug Discov Today 2009;14:589-97
   PubMed Web of Science ®Google Scholar
• Cavero I, Mestre M, Guillon JM, Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000;1:947-73
   PubMedGoogle Scholar
• Eckardt L, Haverkamp W, Borggrefe M, Experimental models of torsade de pointes. Cardiovasc Res 1998;39:178-93
   PubMed Web of Science ®Google Scholar
• Lawrence CL, Pollard CE, Hammond TG, Nonclinical proarrhythmia models: predicting torsades de pointes. Pharmacol Toxicol Methods 2006;52:46-59
   Google Scholar
• Steidl-Nichols J-V, Hanton G, Leaney L, Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model. J Pharmacol Toxicol Methods 2008;57:9-22
   PubMedGoogle Scholar
• Liu T, Brown BS, Wu Y, Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-56
   PubMed Web of Science ®Google Scholar
• Van Deuren B, Van Ammel K, Somers Y, The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. J Pharmacol Toxicol Methods 2009;60:11-23
   PubMedGoogle Scholar
• Adeyemi O, Roberts S, Harris J, QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation. J Pharmacol Toxicol Methods 2009;60:159-66
   PubMedGoogle Scholar
• Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 2007;6:465-71
   PubMed Web of Science ®Google Scholar
• Crumb W, Llorca PM, Lancon C, Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur J Pharmacol 200;532:270-8
   PubMed Web of Science ®Google Scholar
• Gwathmey JK, Tsaioun K, Hajjar RJ. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin Drug Metab Toxicol 2009;5:647-60
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Botta G, The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007;293:C12-21
   PubMed Web of Science ®Google Scholar
• Pereira CV, Moreira AC, Pereira SP, Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 2009;4:34-54
   PubMedGoogle Scholar
• Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009;105(Suppl 1):S14-25
   Google Scholar
• Easter A, Bell ME, Damewood JR Jr, Approaches to seizure risk assessment in preclinical drug discovery. Drug Disc Today 2009;14:876-84
   PubMed Web of Science ®Google Scholar
• Guideline on the non-clinical investigation of the dependence potential of medicinal products. Available from: www.emea.europa.eu/pdfs/human/swp/9422704en.pdf
   Google Scholar
• PhRMA-FDA Dialogue Session. February 20, 2008: PhRMA-FDA dialogue session abuse potential assessments. Available from: www.fda.gov/cder/offices/CSS/presentations.htm
   Google Scholar
• Herling AW. Gastro intestinal system. Drug discovery and evaluation: safety and pharmacokinetic assays In: Vogel HD, editor, Hock FG, Maas J, Mayer D, co-editors, Springer-Verlag, Berlin, Heidelberg, New York; 2006. p. 152-76
   Google Scholar
• Emeigh Hart SG. Safety Pharmacology of drugs for the urinary tract. Drug discovery and evaluation: safety and pharmacokinetic assays In: Vogel HD editor Hock FG, Maas J, Mayer, co-editors, Springer-Verlag, Berlin, Heidelberg, New York; 2006. p. 95-140
   Google Scholar
• Gedeck P, Lewis RA. Exploiting QSAR models in lead optimization. Curr Opin Drug Discov Devel 2008;11:569-75
   PubMed Web of Science ®Google Scholar
• Dearden JC. In silico prediction of ADMET properties: how far have we come? Expert Opin Drug Metab Toxicol 2007;3:635-9
   PubMed Web of Science ®Google Scholar
• Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008;300:1887-96
   PubMed Web of Science ®Google Scholar
• Vargas HM, Bass AS, Breidenbach A, Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 2008;58:72-6
   PubMedGoogle Scholar
• ICH Harmonised Tripartite Guideline. Safety evaluation of biotechnology-derived pharmaceuticals. S6. Available from: www.ich.org/LOB/media/MEDIA503. pdf
   Google Scholar
• Bussiere JL, Martin P, Horner M, Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 2009;28:230-53
   PubMed Web of Science ®Google Scholar
• Trepakova ES, Koerner J, Pettit SD, A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 2009;60:45-50
   PubMedGoogle Scholar
• Available from: www.c-path.org/pstc.cfm
   Google Scholar
• Valentin JP, Price, S. Overview of the modular training programme in applied toxicology: Module on safety pharmacology in pre-clinical research and development. Br Toxicol Newsletter 2007;30:63-5
   Google Scholar
• Bass AS, Cartwright ME, Mahon C, Exploratory drug safety: a discovery strategy to reduce attrition in development. J Pharmacol Toxicol Methods 2009;60:69-78
   Google Scholar